JP6847958B2 - がんの治療方法 - Google Patents

がんの治療方法 Download PDF

Info

Publication number: JP6847958B2
Authority: JP; Japan
Prior art keywords: substituted; unsubstituted; cancer; cells; alkyl
Prior art date: 2015-12-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2018533135A

Other languages

English (en)

Japanese (ja)

Other versions

JP2019503365A5 (2

JP2019503365A (ja

Inventor

ウィリングハム，スティーブン

ミラー，リチャード・エイ

ホー，ポー・ワイ

マカフェリー，イアン

ホットソン，アンドリュー

Original Assignee

コーバス・ファーマシューティカルズ・インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-24

Filing date

2016-12-22

Publication date

2021-03-24

2016-12-22 Application filed by コーバス・ファーマシューティカルズ・インコーポレイテッド filed Critical コーバス・ファーマシューティカルズ・インコーポレイテッド

2019-02-07 Publication of JP2019503365A publication Critical patent/JP2019503365A/ja

2020-06-11 Publication of JP2019503365A5 publication Critical patent/JP2019503365A5/ja

2021-03-24 Application granted granted Critical

2021-03-24 Publication of JP6847958B2 publication Critical patent/JP6847958B2/ja

Status Active legal-status Critical Current

2036-12-22 Anticipated expiration legal-status Critical

Links

0 CC1=CC=C(c2nc(N)nc3c2nn[n]3CC2=CC=CC(CO[C@]3C*CC3)=I2)Cl1 Chemical compound CC1=CC=C(c2nc(N)nc3c2nn[n]3CC2=CC=CC(CO[C@]3C*CC3)=I2)Cl1 0.000 description 6
YJROQMDAKWIJIH-UHFFFAOYSA-N CC1=CC=C(c2nc(N=C)nc3c2nn[n]3Cc2nc(COC3C[IH]CC3)ccc2)[IH]1 Chemical compound CC1=CC=C(c2nc(N=C)nc3c2nn[n]3Cc2nc(COC3C[IH]CC3)ccc2)[IH]1 YJROQMDAKWIJIH-UHFFFAOYSA-N 0.000 description 1
XMMYQZNURBUMJF-XFFZJAGNSA-N CCc1nc(-c2ccc(C)[o]2)c(c(C)n[n]2Cc3cc(C/C=C\C4CCCC4)ccc3)c2c1 Chemical compound CCc1nc(-c2ccc(C)[o]2)c(c(C)n[n]2Cc3cc(C/C=C\C4CCCC4)ccc3)c2c1 XMMYQZNURBUMJF-XFFZJAGNSA-N 0.000 description 1
GYYGWEIOCBBDMB-UHFFFAOYSA-N Cc1ccc(-c2nc(N)nc3c2nn[n]3Cc2nc(CNC3CNCC3)ccc2)[nH]1 Chemical compound Cc1ccc(-c2nc(N)nc3c2nn[n]3Cc2nc(CNC3CNCC3)ccc2)[nH]1 GYYGWEIOCBBDMB-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP2018533135A 2015-12-24 2016-12-22 がんの治療方法 Active JP6847958B2 (ja)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US201562387383P	2015-12-24	2015-12-24
US62/387,383		2015-12-24
US201662324211P	2016-04-18	2016-04-18
US62/324,211		2016-04-18
US201662350602P	2016-06-15	2016-06-15
US62/350,602		2016-06-15
US201662421109P	2016-11-11	2016-11-11
US201662421171P	2016-11-11	2016-11-11
US62/421,171		2016-11-11
US62/421,109		2016-11-11
PCT/US2016/068459 WO2017112917A1 (en)	2015-12-24	2016-12-22	Methods of treating cancer

Publications (3)

Publication Number	Publication Date
JP2019503365A JP2019503365A (ja)	2019-02-07
JP2019503365A5 JP2019503365A5 (2)	2020-06-11
JP6847958B2 true JP6847958B2 (ja)	2021-03-24

Family

ID=59091273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018533135A Active JP6847958B2 (ja)	2015-12-24	2016-12-22	がんの治療方法

Country Status (13)

Country	Link
US (2)	US10912776B2 (2)
EP (1)	EP3393475B1 (2)
JP (1)	JP6847958B2 (2)
KR (1)	KR20180103918A (2)
CN (1)	CN108883107A (2)
AU (1)	AU2016379425B2 (2)
CA (1)	CA3009527C (2)
EA (1)	EA201891509A1 (2)
ES (1)	ES3017686T3 (2)
IL (1)	IL260199B (2)
MX (1)	MX391382B (2)
WO (1)	WO2017112917A1 (2)
ZA (1)	ZA201804227B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6847958B2 (ja) *	2015-12-24	2021-03-24	コーバス・ファーマシューティカルズ・インコーポレイテッド	がんの治療方法
EP3606531A4 (en)	2017-04-04	2021-04-28	Corvus Pharmaceuticals, Inc.	METHOD OF TREATMENT OF CANCER
EP3654982A4 (en)	2017-07-18	2021-04-14	Nuvation Bio Inc.	1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
WO2019018584A1 (en)	2017-07-18	2019-01-24	GiraFpharma LLC	HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CN109293652B (zh) *	2017-07-24	2021-10-22	四川科伦博泰生物医药股份有限公司	一种取代的噻唑衍生物及其用途
CN111093669A (zh) *	2017-08-14	2020-05-01	法斯瑞斯公司	用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂
CN109662966A (zh) *	2017-10-16	2019-04-23	北京莱科金基因科技有限责任公司	伊曲茶碱在制备用于肿瘤治疗的药物中的用途
CN111587113A (zh) *	2017-11-06	2020-08-25	科尔沃斯制药股份有限公司	用于癌症治疗的组合疗法
CN111565722A (zh) *	2017-11-06	2020-08-21	科尔沃斯制药股份有限公司	用于癌症治疗的腺苷路径抑制剂
CN111615389A (zh) *	2018-02-01	2020-09-01	科尔沃斯制药股份有限公司	药物调配物
EP3520782A3 (en)	2018-02-01	2019-11-13	Corvus Pharmaceuticals, Inc.	Pharmaceutical formulations containing adenosine a2a receptor antagonists
BR122023024273A2 (pt)	2018-02-27	2024-02-20	Incyte Corporation	Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en)	2018-05-18	2019-11-21	Incyte Corporation	Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2019233994A1 (en)	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
GEP20237548B (en)	2018-07-05	2023-10-10	Incyte Corp	Fused pyrazine derivatives as a2a /a2b inhibitors
US12174192B2 (en) *	2018-07-12	2024-12-24	Corvus Pharmaceuticals, Inc.	Methods for detecting and treating cancers having adenosine pathway activation
EP3820522A4 (en)	2018-07-12	2022-05-18	Corvus Pharmaceuticals, Inc.	METHODS OF DETECTION AND THERAPY OF CANCER WITH ACTIVATION OF THE ADENOSIN SIGNALING PATHWAY
US20200345725A1 (en)	2019-01-11	2020-11-05	Omeros Corporation	Methods and Compositions for Treating Cancer
EP3911324A4 (en)	2019-01-18	2022-08-17	Nuvation Bio Inc.	1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3911323A4 (en)	2019-01-18	2022-11-16	Nuvation Bio Inc.	HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20200105246A (ko) *	2019-02-28	2020-09-07	한미약품 주식회사	아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
CN112592346B (zh) *	2019-07-30	2022-04-26	厦门宝太生物科技股份有限公司	一种a2a和/或a2b抑制剂中间体的制备方法
US20230332239A1 (en) *	2019-11-26	2023-10-19	Astrazeneca Ab	Methods of treating cancer
IL293670A (en) *	2019-12-09	2022-08-01	Twist Bioscience Corp	Variable nucleic acid libraries for adenosine receptors
MX2022008208A (es) *	2020-01-03	2022-10-21	Incyte Corp	Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
WO2022159620A1 (en) *	2021-01-21	2022-07-28	Twist Bioscience Corporation	Methods and compositions relating to adenosine receptors
CN116898858B (zh) *	2023-08-11	2025-09-23	锦州医科大学	一种治疗非小细胞肺癌的药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPS63501765A (ja)	1985-11-01	1988-07-21	インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド	抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DE69132709T2 (de)	1990-06-29	2002-06-20	Large Scale Biology Corp., Vacaville	Melaninproduktion durch transformierte mikroorganismen
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
US5777085A (en)	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en)	1992-12-01	2001-04-03	Protein Design Labs, Inc.	Humanized antibodies reactive with L-selectin
JP2002531466A (ja)	1998-12-01	2002-09-24	プロテインデザインラブス，インコーポレイテッド	γ−インターフェロンに対するヒト化抗体
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
US7767685B2 (en)	2006-06-29	2010-08-03	King Pharmaceuticals Research And Development, Inc.	Adenosine A2B receptor antagonists
GB0906579D0 (en)	2009-04-16	2009-05-20	Vernalis R&D Ltd	Pharmaceuticals, compositions and methods of making and using the same
CN116059219A (zh)	2015-07-16	2023-05-05	比奥克斯塞尔医疗股份有限公司	一种使用免疫调节治疗癌症的新颖方法
JP6847958B2 (ja)	2015-12-24	2021-03-24	コーバス・ファーマシューティカルズ・インコーポレイテッド	がんの治療方法
EP3606531A4 (en) *	2017-04-04	2021-04-28	Corvus Pharmaceuticals, Inc.	METHOD OF TREATMENT OF CANCER
CN111565722A (zh) *	2017-11-06	2020-08-21	科尔沃斯制药股份有限公司	用于癌症治疗的腺苷路径抑制剂
CN111615389A (zh) *	2018-02-01	2020-09-01	科尔沃斯制药股份有限公司	药物调配物

2016
- 2016-12-22 JP JP2018533135A patent/JP6847958B2/ja active Active
- 2016-12-22 CN CN201680082482.7A patent/CN108883107A/zh active Pending
- 2016-12-22 MX MX2018007765A patent/MX391382B/es unknown
- 2016-12-22 CA CA3009527A patent/CA3009527C/en active Active
- 2016-12-22 EP EP16880133.0A patent/EP3393475B1/en active Active
- 2016-12-22 ES ES16880133T patent/ES3017686T3/es active Active
- 2016-12-22 WO PCT/US2016/068459 patent/WO2017112917A1/en not_active Ceased
- 2016-12-22 AU AU2016379425A patent/AU2016379425B2/en active Active
- 2016-12-22 EA EA201891509A patent/EA201891509A1/ru unknown
- 2016-12-22 KR KR1020187021355A patent/KR20180103918A/ko not_active Ceased
- 2016-12-22 US US16/065,012 patent/US10912776B2/en active Active
2018
- 2018-06-21 IL IL260199A patent/IL260199B/en unknown
- 2018-06-22 ZA ZA2018/04227A patent/ZA201804227B/en unknown
2020
- 2020-12-17 US US17/125,596 patent/US12023337B2/en active Active

Also Published As

Publication number	Publication date
EA201891509A1 (ru)	2019-01-31
US20210154199A1 (en)	2021-05-27
CN108883107A (zh)	2018-11-23
WO2017112917A1 (en)	2017-06-29
AU2016379425A1 (en)	2018-07-12
ZA201804227B (en)	2022-07-27
CA3009527C (en)	2024-01-09
ES3017686T3 (en)	2025-05-13
IL260199B (en)	2022-01-01
KR20180103918A (ko)	2018-09-19
AU2016379425B2 (en)	2021-11-11
CA3009527A1 (en)	2017-06-29
EP3393475A1 (en)	2018-10-31
EP3393475A4 (en)	2019-08-14
US10912776B2 (en)	2021-02-09
MX391382B (es)	2025-03-21
US20190076433A1 (en)	2019-03-14
US12023337B2 (en)	2024-07-02
EP3393475C0 (en)	2025-02-05
IL260199A (en)	2018-07-31
WO2017112917A8 (en)	2018-07-26
JP2019503365A (ja)	2019-02-07
EP3393475B1 (en)	2025-02-05

Legal Events

Date	Code	Title	Description
2019-12-18	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191218
2020-04-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200422
2020-10-22	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201021
2020-10-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027
2021-01-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210113
2021-02-15	TRDD	Decision of grant or rejection written
2021-02-24	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210224
2021-03-05	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210303
2021-03-05	R150	Certificate of patent or registration of utility model	Ref document number: 6847958 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2024-02-29	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-03-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-03-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6847958B2 (ja)	2021-03-24	がんの治療方法
AU2021200091B2 (en)	2021-05-27	Chimeric antigen receptor compositions
JP7109007B2 (ja)	2022-07-29	がん治療の組み合わせ
WO2016200836A1 (en)	2016-12-15	Methods of treating cancer using anti-ox40 antibodies
CN111565722A (zh)	2020-08-21	用于癌症治疗的腺苷路径抑制剂
CN105339008A (zh)	2016-02-17	用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
JP2020517629A (ja)	2020-06-18	抗ｃｄ２５抗体薬物複合体による併用療法
US20190022096A1 (en)	2019-01-24	Methods of treating cancer
CN111587113A (zh)	2020-08-25	用于癌症治疗的组合疗法
HK1263152B (en)	2025-10-10	Ciforadent alone or in combination with atezolizumab for use in treating cancer
HK1263152A1 (en)	2020-01-24	Ciforadent alone or in combination with atezolizumab for use in treating cancer
NZ743653A (en)		Methods of treating cancer
HK40010265A (en)	2020-07-03	Cancer treatment combinations